Healio: Early data shows new treatment effective for pediatric Hodgkin lymphoma patients
UC expert presents clinical trial data at ASCO conference
A new combination treatment for patients with advanced-stage Hodgkin lymphoma is safe and effective in pediatric patients, according to early new clinical trial data.
Robin E. Norris, MD, associate professor in the University of Cincinnati Department of Pediatrics in the College of Medicine and director of clinical research for oncology and co-director of the young adult oncology program at Cincinnati Children's Hospital Medical Center, presented updated data from an ongoing phase 1/phase 2 clinical trial of a new combination treatment at the American Society of Clinical Oncology Annual Meeting in Chicago last week. The presentation was highlighted in a recent article by Healio.
The trial is studying the effectiveness of a drug called brentuximab vedotin, a combination immunotherapy and chemotherapy agent, with other chemotherapy regimens.
The drug has been FDA approved as a first-line therapy for adults, and the clinical trial has shown safety and effectiveness so far with patients aged 5-18.
“These safety and efficacy data are consistent with those seen in adult patients,” Norris said. “These findings support the use of brentuximab plus AVD as a reasonable option for pediatric patients with newly diagnosed, advanced-stage classical Hodgkin lymphoma."
Featured photo at top of human lymphoma tumor cells courtesy of the National Cancer Institute.
Related Stories
UC biologist talks about 'pearmageddon'
March 16, 2026
WLWT talks to UC biologist and Department Head Theresa Culley about invasive, nonnative Callery pear trees that are spreading across Ohio forests after they were introduced by landscapers more than 50 years ago.
Local media highlight completion of Blood Cancer Healing Center fourth and fifth floors
March 16, 2026
Local media including WLWT and the Cincinnati Business Courier highlighted the opening of research laboratories and the UC Osher Wellness Suite and Learning Kitchen at the University of Cincinnati Cancer Center’s Blood Cancer Healing Center.
Trial results support weekly buprenorphine treatment of opioid use disorder during pregnancy
March 16, 2026
Supported by the National Institutes of Health (NIH), researchers led by the University of Cincinnati's John Winhusen published clinical trial results in JAMA Internal Medicine that found administering weekly injectable extended-release buprenorphine for treatment of opioid use disorder during pregnancy led to higher rates of abstinence from illicit opioids than buprenorphine given daily under the tongue, one of the standard methods of treatment.